March 26th, 2025 - Saudi Pharmaceutical Industries and Medical Appliances Corporation( "SPIMACO"; Tadawul: 2070), a national leader in the Saudi pharmaceutical industry, and CanSino Biologics Inc. ( "CanSinoBIO"; SSE: 688185, HKEX: 06185), a leading Chinese biopharmaceutical company specializing in vaccine research, development, production, and commercialization have signed a Collaboration Agreement ( "the Agreement" ) for the supply, manufacturing, and commercialization of MCV4 vaccines in Saudi Arabia and selected MENA markets.

The MCV4 vaccine provides protection against meningococcal disease, a serious bacterial infection that can lead to meningitis and bloodstream infections. It is an essential component of Saudi Arabia's national immunization program and is included in the country's routine childhood vaccination schedule. Additionally, it is a mandatory vaccination for visitors traveling to the country for Hajj and Umrah, ensuring public health safety. CanSinoBIO's MCV4 vaccine, Menhycia® has been launched in China, providing protection for millions of infants. Furthermore, this vaccine has received marketing authorization and a Halal Decree in Indonesia, significantly expanding its reach and impact worldwide.

This collaboration aligns with the Saudi National Biotechnology Strategy, contributing to the country's efforts to enhance vaccine production capabilities, biomanufacturing, and genomics, further strengthening the Kingdom's position in the regional pharmaceutical market.

Dr. Ahmed Aljedai, Chairman of SPIMACO, stated: "We are excited to take this next step in our partnership with CanSinoBIO to bring the MCV4 vaccine to the Saudi and MENA markets. In line with Saudi Vision 2030, the localization of this essential vaccine is part of our broader strategy to develop a strong biopharmaceutical sector in Saudi Arabia."

"Through this agreement, we are expanding our vaccine portfolio and ensuring access to high-quality, locally manufactured vaccines. This collaboration with CanSinoBIO represents a concrete milestone in our efforts to strengthen Saudi Arabia's role as a hub for biopharmaceutical production", added Mr. Jerome Cabannes, CEO of SPIMACO.

Dr. Xuefang Yu, Chief Executive Officer and Chairman of CanSinoBIO, commented:"Our collaboration with SPIMACO is an important milestone for CanSinoBIO to support the market in the Middle East and North Africa countries. CanSinoBIO remains dedicated to providing innovative, high-quality, and affordable vaccines to satisfy the unmet medical demands in the region."

The Agreement was signed and exchanged at the CanSinoBIO headquarters in Tianjin, China.

About SPIMACO

Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO, Tadawul: 2070), headquartered in Riyadh, Saudi Arabia, is a leading pharmaceutical manufacturer operating in 16 countries across the MENA region. SPIMACO specializes in high-quality generics, and serves as a strategic partner for major global and regional pharmaceutical companies. The company operates two state-of-the-art production facilities in Qassim and Dammam, featuring seven production lines with a combined annual capacity exceeding 1,750 million units. SPIMACO's diverse pharmaceutical portfolio includes oral solids and liquids, creams, aseptic injectables, suppositories, and active pharmaceutical ingredients (APIs). With a workforce of over 1,200 employees, SPIMACO is focused on sustainable growth and advancing the pharmaceutical industry in the region.

About CanSinoBIO

Founded in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) develops and manufactures high-quality, innovative, and affordable vaccines for global public health. It possesses five integrated platform technologies, supporting a diverse portfolio of vaccines preventing more than 10 diseases, including Asia's only vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia®, approved in over 10 countries and granted EUL by the WHO, Asia's first Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia® and the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia® approved by NMPA in China.